{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae CA 125 II Assay",
        "VIDAS\u00ae CA 125 IITM",
        "VIDAS@ CA 125 11"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K080561",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023891"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTK"
    ],
    "Summary Letter Date": "April 07, 2009",
    "Summary Letter Received Date": "April 08, 2009",
    "Submission Date": "October 8, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "CA 125",
        "OC 125 reactive antigenic determinants"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VIDAS instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked fluorescent assay (ELFA)",
        "Immunoassay sandwich method"
    ],
    "Methodologies": [
        "Immunoassay",
        "Sandwich method",
        "Fluorescent detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS CA 125 II automated immunoassay for quantitative measurement of CA 125 antigen in serum using ELFA technology for ovarian cancer monitoring",
    "Indications for Use Summary": "Automated quantitative test for measurement of OC 125 reactive antigenic determinants in human serum to aid in monitoring and recurrence detection in patients previously diagnosed with ovarian cancer",
    "fda_folder": "Immunology"
}